Poor response to pegylated interferon and ribavirin in older women infected with hepatitis C virus of genotype 1b in high viral loads

Digestive Diseases and Sciences

Volumn 54, Issue 6, 2009, Pages 1317-1324

  Sezaki, Hitomi ^a   Suzuki, Fumitaka ^a   Kawamura, Yusuke ^a   Yatsuji, Hiromi ^a   Hosaka, Tetsuya ^a   Akuta, Norio ^a   Kobayashi, Masahiro ^a   Suzuki, Yoshiyuki ^a   Saitoh, Satoshi ^a   Arase, Yasuji ^a   Ikeda, Kenji ^a   Miyakawa, Yuzo ^b   Kumada, Hiromitsu ^a  

^a TORANOMON HOSPITAL   (Japan)

^b Miyakawa Memorial Research Foundation   (Japan)

Author keywords

Aging; Chronic hepatitis C; Genotypes; Interferon; Ribavirin; Women

Indexed keywords

ESTROGEN; INDOCYANINE GREEN; PEGINTERFERON ALPHA2B; RIBAVIRIN;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CLINICAL EVALUATION; CONTROLLED STUDY; DRUG RESPONSE; ESTROGEN BLOOD LEVEL; FEMALE; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SEX DIFFERENCE; TREATMENT RESPONSE; VIRUS LOAD;

ADULT; AGED; AGING; ANTIVIRAL AGENTS; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C; HUMANS; INTERFERON ALFA-2B; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RIBAVIRIN; SEX CHARACTERISTICS; VIRAL LOAD; YOUNG ADULT;

EID: 67349254235     PISSN: 01632116     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10620-008-0500-y     Document Type: Article

References (39)

1. J Cohen 1999 The scientific challenge of hepatitis C Science 285 26 30 10.1126/science.285.5424.26
2. A Alberti L Chemello L Benvegnu 1999 Natural history of hepatitis C J Hepatol 31 S17 S24 10.1016/S0168-8278(99)80369-9 (Pubitemid 30002686)
3. HJ Alter LB Seeff 2000 Recovery, persistence, and sequelae in hepatitis C virus infection: a perspective on long-term outcome Semin Liver Dis 20 17 35 10.1055/s-2000-9505 (Pubitemid 30421406)
4. LB Seeff 2002 Natural history of chronic hepatitis C Hepatology 36 S35 S46 10.1002/hep.1840360706 (Pubitemid 35253462)
5. C Feray M Gigou D Samuel V Paradis S Mishiro G Maertens 1995 Influence of the genotypes of hepatitis C virus on the severity of recurrent liver disease after liver transplantation Gastroenterology 108 1088 1096 10.1016/0016-5085(95) 90207-4
6. J Garcia-Samaniego V Soriano J Castilla R Bravo A Moreno J Carbo 1997 Influence of hepatitis C virus genotypes and HIV infection on histological severity of chronic hepatitis C Am J Gastroenterol 92 1130 1134 (Pubitemid 27304807)
7. GP Pageaux J Ducos AM Mondain V Costes MC Picot PF Perrigault 1997 Hepatitis C virus genotypes and quantitation of serum hepatitis C virus RNA in liver transplant recipients: relationship with severity of histological recurrence and implications in the pathogenesis of HCV infection Liver Transpl Surg 3 501 505 10.1002/lt.500030504 (Pubitemid 27427899)
8. E Kenny-Walsh 1999 Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. Irish Hepatology Research Group N Engl J Med 340 1228 1233 10.1056/NEJM199904223401602 (Pubitemid 29181642)
9. T Poynard P Bedossa P Opolon 1997 Natural history of liver fibrosis progression in patients with chronic hepatitis C Lancet 349 825 832 10.1016/S0140-6736(96)07642-8 (Pubitemid 27129209)
10. M Vogt T Lang G Frosner C Klingler AF Sendl A Zeller 1999 Prevalence and clinical outcome of hepatitis C infection in children who underwent cardiac surgery before the implementation of blood-donor screening N Engl J Med 341 866 870 10.1056/NEJM199909163411202 (Pubitemid 29427048)
11. JG McHutchison SC Gordon ER Schiff ML Shiffman WM Lee VK Rustgi 1998 Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C N Engl J Med 339 1485 1492 10.1056/NEJM199811193392101 (Pubitemid 28543496)
12. MW Fried ML Shiffman KR Reddy C Smith G Marinos FL Goncales Jr 2002 Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection N Engl J Med 347 975 982 10.1056/NEJMoa020047
13. CH Hung CM Lee SN Lu JH Wang CH Chen TH Hu 2006 Anemia associated with antiviral therapy in chronic hepatitis C: incidence, risk factors, and impact on treatment response Liver Int 26 1079 1086 10.1111/j.1478-3231.2006.01354.x (Pubitemid 44541749)
14. N Akuta F Suzuki Y Kawamura H Yatsuji H Sezaki Y Suzuki 2007 Predictors of viral kinetics to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b J Med Virol 79 1686 1695 10.1002/jmv.20979 (Pubitemid 47479887)
15. H Sezaki F Suzuki Y Kawamura H Yatsuji T Hosaka N Akuta 2007 Evaluation of long-term biochemical responses to combination therapy of interferon plus ribavirin in those infected with hepatitis C virus genotype 1b and high baseline viral load Hepatol Res 37 787 792 10.1111/j.1872-034X.2007.00132.x (Pubitemid 47308219)
16. HS Conjeevaram MW Fried LJ Jeffers NA Terrault TE Wiley-Lucas N Afdhal 2006 Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1 Gastroenterology 131 470 477 10.1053/j.gastro.2006.06.008 (Pubitemid 44142464)
17. T Poynard P Marcellin SS Lee C Niederau GS Minuk G Ideo 1998 Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT) Lancet 352 1426 1432 10.1016/S0140-6736(98)07124-4 (Pubitemid 28510876)
18. A Tsubota K Chayama K Ikeda A Yasuji I Koida S Saitoh 1994 Factors predictive of response to interferon-alpha therapy in hepatitis C virus infection Hepatology 19 1088 1094 (Pubitemid 24134229)
19. SJ Hadziyannis H Sette Jr TR Morgan V Balan M Diago P Marcellin 2004 Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose Ann Intern Med 140 346 355 (Pubitemid 38268915)
20. CK Hui MF Yuen E Sablon AO Chan BC Wong CL Lai 2003 Interferon and ribavirin therapy for chronic hepatitis C virus genotype 6: a comparison with genotype 1 J Infect Dis 187 1071 1074 10.1086/368217 (Pubitemid 36399349)
21. F Legrand-Abravanel F Nicot A Boulestin K Sandres-Saune JP Vinel L Alric 2005 Pegylated interferon and ribavirin therapy for chronic hepatitis C virus genotype 4 infection J Med Virol 77 66 69 10.1002/jmv.20414 (Pubitemid 41076478)
22. MF Yuen CL Lai 2006 Response to combined interferon and ribavirin is better in patients infected with hepatitis C virus genotype 6 than genotype 1 in Hong Kong Intervirology 49 96 98 10.1159/000087270 (Pubitemid 41318183)
23. T Kumada H Toyoda T Honda T Kuzuya Y Katano I Nakano 2006 Treatment of chronic hepatitis C with interferon alone or combined with ribavirin in Japan Intervirology 49 112 118 10.1159/000087273 (Pubitemid 41318186)
24. TJ Liang B Rehermann LB Seeff JH Hoofnagle 2000 Pathogenesis, natural history, treatment, and prevention of hepatitis C Ann Intern Med 132 296 305 (Pubitemid 30106261)
25. C Trepo 2000 Genotype and viral load as prognostic indicators in the treatment of hepatitis C J Viral Hepat 7 250 257 10.1046/j.1365-2893.2000.00233. x (Pubitemid 30470011)
26. M Wali RF Harrison PJ Gow D Mutimer 2002 Advancing donor liver age and rapid fibrosis progression following transplantation for hepatitis C Gut 51 248 252 10.1136/gut.51.2.248
27. S Takaki A Tsubota T Hosaka N Akuta T Someya M Kobayashi 2004 Factors contributing to ribavirin dose reduction due to anemia during interferon alfa2b and ribavirin combination therapy for chronic hepatitis C J Gastroenterol 39 668 673 10.1007/s00535-003-1363-9 (Pubitemid 39149355)
28. J Hayashi Y Kishihara K Ueno K Yamaji Y Kawakami N Furusyo 1998 Age-related response to interferon alfa treatment in women vs men with chronic hepatitis C virus infection Arch Intern Med 158 177 181 10.1001/archinte.158.2. 177 (Pubitemid 28049511)
29. S Khosla LJ Melton 3rd EJ Atkinson WM O'Fallon GG Klee BL Riggs 1998 Relationship of serum sex steroid levels and bone turnover markers with bone mineral density in men and women: a key role for bioavailable estrogen J Clin Endocrinol Metab 83 2266 2274 10.1210/jc.83.7.2266 (Pubitemid 28503012)
30. M Yasuda I Shimizu M Shiba S Ito 1999 Suppressive effects of estradiol on dimethylnitrosamine-induced fibrosis of the liver in rats Hepatology 29 719 727 10.1002/hep.510290307 (Pubitemid 29109585)
31. GP Rossini GM Baldini E Villa F Manenti 1989 Characterization of estrogen receptor from human liver Gastroenterology 96 1102 1109 (Pubitemid 19091126)
32. M Shiba I Shimizu M Yasuda K Ii S Ito 1998 Expression of type I and type III collagens during the course of dimethylnitrosamine-induced hepatic fibrosis in rats Liver 18 196 204 (Pubitemid 28368071)
33. V Di Martino P Lebray RP Myers E Pannier V Paradis F Charlotte 2004 Progression of liver fibrosis in women infected with hepatitis C: long-term benefit of estrogen exposure Hepatology 40 1426 1433 10.1002/hep.20463 (Pubitemid 39657018)
34. M Sartori S Andorno C Rigamonti E Grossini G Nicosia R Boldorini 2000 Chronic hepatitis C is mild in menstruating women J Gastroenterol Hepatol 15 1411 1417 10.1046/j.1440-1746.2000.02368.x (Pubitemid 32052915)
35. NC Latt JD Spencer PJ Beeby GW McCaughan JB Saunders E Collins 2000 Hepatitis C in injecting drug-using women during and after pregnancy J Gastroenterol Hepatol 15 175 181 10.1046/j.1440-1746.2000.02060.x (Pubitemid 30154411)
36. RA Levine SO Sanderson R Ploutz-Snyder F Murray E Kay J Hegarty 2006 Assessment of fibrosis progression in untreated Irish women with chronic hepatitis C contracted from immunoglobulin anti-D Clin Gastroenterol Hepatol 4 1271 1277 10.1016/j.cgh.2006.05.028 (Pubitemid 44512210)
37. M Wiese F Berr M Lafrenz H Porst U Oesen 2000 Low frequency of cirrhosis in a hepatitis C (genotype 1b) single-source outbreak in Germany: a 20-year multicenter study Hepatology 32 91 96 10.1053/jhep.2000.8169 (Pubitemid 30432371)
38. GD Braunstein 1993 Gynecomastia N Engl J Med 328 490 495 10.1056/NEJM199302183280708 (Pubitemid 23056441)
39. EJ Carey V Balan WK Kremers JE Hay 2003 Osteopenia and osteoporosis in patients with end-stage liver disease caused by hepatitis C and alcoholic liver disease: not just a cholestatic problem Liver Transpl 9 1166 1173 10.1053/jlts.2003.50242 (Pubitemid 37407985)